Manidipine
A dihydropyridine calcium channel blocker.
General information
Manidipine is a calcium channel blocker used for hypertension management. It acts on vasculature without having effects on the heart (DrugBank).
Manidipine on PubChem
Manidipine on Wikipedia
Marketed as
MANYPER
CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19
Preprint In vitro Screening |
HeLa-ACE2 cells | Jun/16/2020 | ||
|
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
3CLpro Small molecule Enzyme assay In vitro |
in vitro enzyme assay | 3.75 | Inhibited the SARS-CoV-2 3C-like protease in vitro with IC50 of 4.8 μM. |
Oct/25/2020 |
|
Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
3CLpro PapainLpro Small molecule Enzyme assay In vitro |
in vitro enzyme assay; Vero E6 cells | 4.92 | The dihydrochloride salt of the compound inhibited the SARS-CoV-2 3C-like protease and Papain-like protease in a dose-dependent manner in vitro. It protected Vero E6 cells from viral infection with EC50 of 14.5 μM and SI of >6.9. It was determined to be active at the post-entry stage of infection. |
Feb/01/2021 |
